{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:09:48Z","timestamp":1792613388525,"version":"4.5.0"},"reference-count":50,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.3201\/eid3103.241488","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:57:16Z","timestamp":1740178636000},"source":"Crossref","is-referenced-by-count":6,"title":["High Prevalence of <i>atpE<\/i> Mutations in Bedaquiline-Resistant <i>Mycobacterium tuberculosis<\/i> Isolates, Russia"],"prefix":"10.3201","volume":"31","author":[{"given":"Danila","family":"Zimenkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ushtanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Gordeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guselnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakov","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Stavitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3103.241488-202502131131-R1","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: The Organization; 2023."},{"key":"key-10.3201\/eid3103.241488-202502131131-R2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJMe2300413","article-title":"Shortening tuberculosis treatment\u2014a strategic retreat.","volume":"388","author":"Dartois","year":"2023","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3103.241488-202502131131-R3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"key-10.3201\/eid3103.241488-202502131131-R4","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/ncomms4369","article-title":"Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.","volume":"5","author":"Koul","year":"2014","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid3103.241488-202502131131-R5","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R6","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline.","volume":"9","author":"Andries","year":"2014","journal-title":"PLoS One"},{"key":"key-10.3201\/eid3103.241488-202502131131-R7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1183\/09031936.00142914","article-title":"A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.","volume":"45","author":"Somoskovi","year":"2015","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3103.241488-202502131131-R8","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3103.241488-202502131131-R9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/jac\/dkx094","article-title":"Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.","volume":"72","author":"Zimenkov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R10","doi-asserted-by":"publisher","first-page":"e1003120","DOI":"10.1371\/journal.ppat.1003120","article-title":"Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis.","volume":"9","author":"Wells","year":"2013","journal-title":"PLoS Pathog"},{"key":"key-10.3201\/eid3103.241488-202502131131-R11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13073-024-01311-w","article-title":"The exceptions that prove the rule-a historical view of bedaquiline susceptibility.","volume":"16","author":"Miotto","year":"2024","journal-title":"Genome Med"},{"key":"key-10.3201\/eid3103.241488-202502131131-R12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jinf.2020.01.007","article-title":"Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.","volume":"80","author":"Peretokina","year":"2020","journal-title":"J Infect"},{"key":"key-10.3201\/eid3103.241488-202502131131-R13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5588\/ijtld.21.0670","article-title":"Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.","volume":"26","author":"Kaniga","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid3103.241488-202502131131-R14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12941-023-00568-0","article-title":"Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China.","volume":"22","author":"Hu","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"key-10.3201\/eid3103.241488-202502131131-R15","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"key-10.3201\/eid3103.241488-202502131131-R16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase.","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R17","doi-asserted-by":"publisher","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review.","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"key-10.3201\/eid3103.241488-202502131131-R18","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd edition. Geneva: The Organization: 2023."},{"key":"key-10.3201\/eid3103.241488-202502131131-R19","doi-asserted-by":"publisher","first-page":"e0116421","DOI":"10.1128\/AAC.01164-21","article-title":"Role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex.","volume":"65","author":"Vargas","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R20","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: The Organization; 2018."},{"key":"key-10.3201\/eid3103.241488-202502131131-R21","doi-asserted-by":"publisher","first-page":"e3001721","DOI":"10.1371\/journal.pbio.3001721","article-title":"A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.","volume":"20","author":"The CRyPTIC Consortium","year":"2022","journal-title":"PLoS Biol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R22","doi-asserted-by":"publisher","first-page":"16526","DOI":"10.1074\/jbc.M113.538959","article-title":"Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis.","volume":"289","author":"Radhakrishnan","year":"2014","journal-title":"J Biol Chem"},{"key":"key-10.3201\/eid3103.241488-202502131131-R23","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1128\/AAC.06227-11","article-title":"rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.","volume":"56","author":"Beckert","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tube.2018.04.007","article-title":"Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.","volume":"111","author":"Martinez","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"key-10.3201\/eid3103.241488-202502131131-R25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cmi.2020.08.030","article-title":"Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment.","volume":"27","author":"Mokrousov","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"key-10.3201\/eid3103.241488-202502131131-R26","doi-asserted-by":"publisher","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country.","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3103.241488-202502131131-R27","doi-asserted-by":"publisher","first-page":"2102102","DOI":"10.1183\/13993003.02102-2021","article-title":"In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient.","volume":"59","author":"Ghodousi","year":"2022","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3103.241488-202502131131-R28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3201\/eid2805.212517","article-title":"atpE mutation in Mycobacterium tuberculosis not always predictive of bedaquiline treatment failure.","volume":"28","author":"Le Ray","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3103.241488-202502131131-R29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2023.04.003","article-title":"Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients.","volume":"33","author":"Shang","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"key-10.3201\/eid3103.241488-202502131131-R30","doi-asserted-by":"publisher","first-page":"e0374923","DOI":"10.1128\/spectrum.03749-23","article-title":"Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia.","volume":"12","author":"Umpeleva","year":"2024","journal-title":"Microbiol Spectr"},{"key":"key-10.3201\/eid3103.241488-202502131131-R31","doi-asserted-by":"publisher","first-page":"e0311042","DOI":"10.1371\/journal.pone.0311042","article-title":"Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China.","volume":"19","author":"Peng","year":"2024","journal-title":"PLoS One"},{"key":"key-10.3201\/eid3103.241488-202502131131-R32","doi-asserted-by":"publisher","first-page":"2400391","DOI":"10.1183\/13993003.00391-2024","article-title":"A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex.","volume":"64","author":"K\u00f6ser","year":"2024","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3103.241488-202502131131-R33","doi-asserted-by":"publisher","first-page":"e0333922","DOI":"10.1128\/spectrum.03339-22","article-title":"The global success of Mycobacterium tuberculosis modern Beijing family is driven by a few recently emerged strains.","volume":"11","author":"Zhu","year":"2023","journal-title":"Microbiol Spectr"},{"key":"key-10.3201\/eid3103.241488-202502131131-R34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/microorganisms11020255","article-title":"Genetic diversity and primary drug resistance of Mycobacterium tuberculosis Beijing genotype strains in northwestern Russia.","volume":"11","author":"Vyazovaya","year":"2023","journal-title":"Microorganisms"},{"key":"key-10.3201\/eid3103.241488-202502131131-R35","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R36","doi-asserted-by":"publisher","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","article-title":"Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan.","volume":"12","author":"Wu","year":"2021","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R37","doi-asserted-by":"publisher","first-page":"e0009023","DOI":"10.1128\/spectrum.00090-23","article-title":"Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis.","volume":"11","author":"Shi","year":"2023","journal-title":"Microbiol Spectr"},{"key":"key-10.3201\/eid3103.241488-202502131131-R38","doi-asserted-by":"publisher","first-page":"e3002874","DOI":"10.1371\/journal.pbio.3002874","article-title":"Structures of the mycobacterial MmpL4 and MmpL5 transporters provide insights into their role in siderophore export and iron acquisition.","volume":"22","author":"Maharjan","year":"2024","journal-title":"PLoS Biol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R39","doi-asserted-by":"publisher","first-page":"e00518","DOI":"10.1128\/mSphere.00518-20","article-title":"Coexpression of MmpS5 and MmpL5 contributes to both efflux transporter MmpL5 trimerization and drug resistance in Mycobacterium tuberculosis.","volume":"6","author":"Yamamoto","year":"2021","journal-title":"MSphere"},{"key":"key-10.3201\/eid3103.241488-202502131131-R40","doi-asserted-by":"publisher","first-page":"e0162922","DOI":"10.1128\/aac.01629-22","article-title":"Intricate link between siderophore secretion and drug efflux in Mycobacterium tuberculosis.","volume":"67","author":"Meikle","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41586-024-07605-8","article-title":"Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587.","volume":"631","author":"Zhang","year":"2024","journal-title":"Nature"},{"key":"key-10.3201\/eid3103.241488-202502131131-R42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1099\/mic.0.054064-0","article-title":"Alanine racemase mutants of Mycobacterium tuberculosis require D-alanine for growth and are defective for survival in macrophages and mice.","volume":"158","author":"Awasthy","year":"2012","journal-title":"Microbiology (Reading)"},{"key":"key-10.3201\/eid3103.241488-202502131131-R43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41588-017-0029-0","article-title":"Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis.","volume":"50","author":"Coll","year":"2018","journal-title":"Nat Genet"},{"key":"key-10.3201\/eid3103.241488-202502131131-R44","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/jac\/dkx316","article-title":"Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.","volume":"72","author":"Chen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid3103.241488-202502131131-R45","doi-asserted-by":"publisher","first-page":"1076797","DOI":"10.3389\/fmicb.2022.1076797","article-title":"Pan-genome association study of Mycobacterium tuberculosis lineage-4 revealed specific genes related to the high and low prevalence of the disease in patients from the North-Eastern area of Medell\u00edn, Colombia.","volume":"13","author":"Hurtado-P\u00e1ez","year":"2023","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R46","doi-asserted-by":"publisher","first-page":"e0043921","DOI":"10.1128\/mbio.00439-21","article-title":"Pyrazinamide susceptibility is driven by activation of the SigE-dependent cell envelope stress response in Mycobacterium tuberculosis.","volume":"13","author":"Thiede","year":"2021","journal-title":"MBio"},{"key":"key-10.3201\/eid3103.241488-202502131131-R47","doi-asserted-by":"crossref","unstructured":"Vilch\u00e8ze C, Jacobs WR. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr. 2014;2:MGM2\u20130014\u20132013.","DOI":"10.1128\/microbiolspec.MGM2-0014-2013"},{"key":"key-10.3201\/eid3103.241488-202502131131-R48","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1086\/652497","article-title":"Genetic requirements for the survival of tubercle bacilli in primates.","volume":"201","author":"Dutta","year":"2010","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3103.241488-202502131131-R49","doi-asserted-by":"publisher","first-page":"140106","DOI":"10.1098\/rsob.140106","article-title":"Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states.","volume":"4","author":"Salina","year":"2014","journal-title":"Open Biol"},{"key":"key-10.3201\/eid3103.241488-202502131131-R50","doi-asserted-by":"publisher","first-page":"1063453","DOI":"10.3389\/fphar.2022.1063453","article-title":"Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies.","volume":"13","author":"Alffenaar","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:57:19Z","timestamp":1740178639000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/3\/24-1488_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3103.241488","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}